Dr Glynn Wilson | Chairman and Strategic Advisor
TapImmune Inc

Dr Glynn Wilson, Chairman and Strategic Advisor, TapImmune Inc

Dr. Wilson brings an extensive background of success in corporate management and product development with tenures in both major multinational pharmaceutical companies and start-up pharmaceutical/biotech organizations. Dr. Wilson’s former positions include Head of Drug Delivery at SmithKline Beecham Pharmaceuticals, Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals, and President and co-founder of Auriga Pharmaceuticals. As Executive Vice President of R&D at Tacora Corporation he was responsible for merging the Company with Access Pharmaceuticals. He is a recognized leader in the development of drug delivery systems. Dr. Wilson has a Ph.D. in Biochemistry and conducted medical research at The Rockefeller University, New York


Agenda Day 1 @ 3:45

Increasing the potency of DNA-based immunotherapies using PolyStart peptide expression system

  • PolyStart is a unique plasmid DNA construct that expresses four or more peptides for each molecule of mRNA, rather than the dogmatic one DNA = one RNA = one protein
  • How PolyStart can increase the efficiency with which target cells can be identified and elminated
  • Applications in immuno-oncology and potential for use in infectious disease

back to speakers